Summary of COVID-19 DFV890 studies

1. Madurka et al., DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

142 patient DFV890 late treatment RCT: 3% higher mortality (p=1) and 1% worse recovery (p=0.95).
RCT 143 hospitalized patients with COVID-19 pneumonia showing no significant difference in APACHE II scores with DFV890 (NLRP3 inhibitor).
Sep 2022, Infection, https://link.springer.com/10.1007/s15010-022-01904-w, https://c19p.org/madurka